Key Highlights

  • Enovis will release third quarter 2026 results on Thursday, November 5, 2026, and hold an investor call and webcast afterward, with no results figures out before that date.
  • Undated screen data showed the shares at USD 24.00, a 14.86% gain, alongside a 30.94% one-year EPS change that remains unverified.
  • For the third quarter of 2025, published coverage of the call cited adjusted EPS of USD 0.75, a 3% rise, and Revenue growth of 9% as reported and 7% organic.
  • Published coverage links a USD 548 million non-cash Goodwill Impairment from 2025 to a sustained slide in the share price and market value, which still clouds GAAP comparisons.

Third-Quarter Report Due November 5, 2026 Makes This a Preview

Enovis (NYSE:ENOV) lists its third quarter 2026 results date as Thursday, November 5, 2026, with a release, then an investor call and webcast. The company is described here as a medical technology company, a background point not drawn from a 2026 filing. Through November 4, 2026, this research found no 2026 revenue, Earnings or guidance figures, so the piece is a preview rather than a results article. One calendar listing shows the stock down 38.5% since its last earnings release, a figure that is published market data and unverified. Consensus estimates were not located. Because the report is still upcoming, any move cited is a snapshot rather than a reaction to results.

Last Year's Third Quarter Sets the Bar for Adjusted Profit

In the third quarter of 2025, Enovis (NYSE:ENOV) posted adjusted EPS of USD 0.75, a 3% gain, with revenue up 9% as reported and 7% organic, as relayed by published coverage. The company lifted its full-year 2025 adjusted EBITDA guidance by USD 3 million, to a range of USD 395 million to USD 405 million, and raised adjusted EPS guidance by USD 0.05, to USD 3.10 to USD 3.25, after adjusting for the Dr. Comfort divestiture. The same coverage tied a USD 548 million non-cash goodwill impairment to a sustained decline in Market Value and share price, a Factor that complicates GAAP comparisons. No adjusted figures for 2026 were published in the material reviewed.

Why the 30.94% EPS Screen Figure Needs Care

The screen places Enovis (NYSE:ENOV) among aggressive small caps with a 30.94% one-year EPS change, but neither the change nor the size label was verified, and the basis, GAAP or adjusted, is unknown. The prior-year GAAP figures were skewed by the USD 548 million impairment, which means a GAAP comparison can show a large apparent swing off a negative base. Starting from about USD 24.00, a 14.86% jump would be a big move for a medical device company. No catalyst surfaced. This piece does not forecast the results or the market reaction. The main risks are a disappointing guidance update, further impairment charges if the share price stays low and a fading of the pre-report rally, factors that could outweigh a solid quarter.

Where Things Stand

Nothing confirms what drove the move. Enovis (NYSE:ENOV) reports on November 5, 2026. The 14.86% gain, USD 24.00 price and 30.94% EPS figure all remain undated, unverified screen data. Documented anchors are the prior-year adjusted EPS mark of USD 0.75, the 2025 guidance raise and the impairment that complicates GAAP comparisons. Investors will weigh the new revenue, adjusted EPS and guidance against those reference points, and any screen-driven rally could fade once the report is out. Until then the framing remains a preview.